JP2017538690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538690A5 JP2017538690A5 JP2017527790A JP2017527790A JP2017538690A5 JP 2017538690 A5 JP2017538690 A5 JP 2017538690A5 JP 2017527790 A JP2017527790 A JP 2017527790A JP 2017527790 A JP2017527790 A JP 2017527790A JP 2017538690 A5 JP2017538690 A5 JP 2017538690A5
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- alkyl
- configuration
- compound
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 25
- 125000000217 alkyl group Chemical group 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- 125000001475 halogen functional group Chemical group 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- -1 benzyl ester Chemical class 0.000 description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000006345 epimerization reaction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000006239 protecting group Chemical class 0.000 description 3
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 2
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- 0 CC(C)[C@]([C@](*)C1)[C@@](CCC(*)CC2[C@@](C)(CCC(C3)=O)C3(C)[C@@]3C)C1C2C3=O Chemical compound CC(C)[C@]([C@](*)C1)[C@@](CCC(*)CC2[C@@](C)(CCC(C3)=O)C3(C)[C@@]3C)C1C2C3=O 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JHWIEAWILPSRMU-UHFFFAOYSA-N 2-methyl-3-pyrimidin-4-ylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=NC=N1 JHWIEAWILPSRMU-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000006809 Jones oxidation reaction Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical group [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1420594.2 | 2014-11-19 | ||
| GBGB1420594.2A GB201420594D0 (en) | 2014-11-19 | 2014-11-19 | Compounds |
| GBGB1420593.4A GB201420593D0 (en) | 2014-11-19 | 2014-11-19 | Compounds |
| GB1420593.4 | 2014-11-19 | ||
| GBGB1505676.5A GB201505676D0 (en) | 2015-04-01 | 2015-04-01 | Compounds |
| GB1505676.5 | 2015-04-01 | ||
| PCT/GB2015/053518 WO2016079519A1 (en) | 2014-11-19 | 2015-11-19 | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538690A JP2017538690A (ja) | 2017-12-28 |
| JP2017538690A5 true JP2017538690A5 (enExample) | 2019-01-10 |
| JP6735748B2 JP6735748B2 (ja) | 2020-08-05 |
Family
ID=54704021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527790A Active JP6735748B2 (ja) | 2014-11-19 | 2015-11-19 | ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−３，７−ジオン−ステロイド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10538550B2 (enExample) |
| EP (1) | EP3221333B1 (enExample) |
| JP (1) | JP6735748B2 (enExample) |
| KR (1) | KR102546748B1 (enExample) |
| CN (1) | CN107108688B (enExample) |
| CA (1) | CA2968305A1 (enExample) |
| DK (1) | DK3221333T3 (enExample) |
| EA (1) | EA034739B1 (enExample) |
| ES (1) | ES2748692T3 (enExample) |
| MX (1) | MX375865B (enExample) |
| PL (1) | PL3221333T3 (enExample) |
| TW (1) | TWI686401B (enExample) |
| WO (1) | WO2016079519A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI686400B (zh) | 2014-11-19 | 2020-03-01 | 英商Ｎｚｐ英國有限公司 | 化合物（二） |
| MX375863B (es) | 2014-11-19 | 2025-03-07 | Nzp Uk Ltd | Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) |
| EA033603B1 (ru) | 2014-11-19 | 2019-11-08 | Nzp Uk Ltd | 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| EA201891491A1 (ru) * | 2015-12-22 | 2018-11-30 | Интерсепт Фармасьютикалз, Инк. | Полиморфные кристаллические формы обетихолевой кислоты |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608779D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| EP3431486A1 (en) | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| US12186329B2 (en) | 2018-08-23 | 2025-01-07 | President And Fellows Of Harvard College | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes |
| CN111138509B (zh) * | 2018-11-02 | 2022-12-06 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的制备方法 |
| EP3890745B1 (en) * | 2018-12-04 | 2025-11-19 | President and Fellows of Harvard College | Synthetic derivatives of cholic acid 7-sulfate and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624748A (en) | 1950-09-09 | 1953-01-06 | Upjohn Co | Bisnorchola-4, 6-dien-3-one-22-al |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| WO1993021259A1 (en) | 1992-04-14 | 1993-10-28 | Cornell Research Foundation Inc. | Dendritic based macromolecules and method of production |
| WO1994019366A1 (en) | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US7138390B2 (en) * | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
| US20090062256A1 (en) | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| KR100948532B1 (ko) | 2001-11-07 | 2010-03-23 | 넥타르 테라퓨틱스 | 분지형 중합체 및 그의 공액체 |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| JP2007210888A (ja) * | 2006-01-12 | 2007-08-23 | Mitsubishi Chemicals Corp | ステロイド化合物の製造方法 |
| CN101395170A (zh) | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| WO2008002573A2 (en) | 2006-06-27 | 2008-01-03 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
| CA2928178C (en) | 2007-01-19 | 2019-09-10 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| EA020310B1 (ru) * | 2008-07-30 | 2014-10-30 | Интерсепт Фармасьютикалз, Инк. | Модуляторы рецептора tgr5 и их применение |
| ES2592452T3 (es) * | 2008-11-19 | 2016-11-30 | Intercept Pharmaceuticals, Inc. | Moduladores de TGR5 y métodos de uso de los mismos |
| AU2009316566B9 (en) | 2008-11-19 | 2014-05-15 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and method of use thereof |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| WO2014066819A1 (en) | 2012-10-26 | 2014-05-01 | Intercept Pharmaceuticals, Inc. | Process for preparing bile acid derivatives |
| KR102106186B1 (ko) * | 2012-11-28 | 2020-05-04 | 인터셉트 파마슈티컬즈, 인크. | 폐 질환의 치료 |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| HRP20180931T1 (hr) | 2013-05-14 | 2018-10-05 | Intercept Pharmaceuticals, Inc. | 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x |
| RU2015155552A (ru) | 2013-05-24 | 2017-06-27 | Нестек С.А. | Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника |
| WO2015183794A1 (en) | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
| ES2938874T3 (es) | 2014-05-29 | 2023-04-17 | Bar Pharmaceuticals S R L | Derivados de colano para su uso en el tratamiento y/o prevención de enfermedades mediadas por FXR y TGR5/GPBAR1 |
| CA2966885A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| MX375863B (es) | 2014-11-19 | 2025-03-07 | Nzp Uk Ltd | Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) |
| EA033603B1 (ru) | 2014-11-19 | 2019-11-08 | Nzp Uk Ltd | 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| TWI686400B (zh) | 2014-11-19 | 2020-03-01 | 英商Ｎｚｐ英國有限公司 | 化合物（二） |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| HK1244708A1 (zh) | 2014-11-26 | 2018-08-17 | 英安塔制药有限公司 | 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
| CN106279328A (zh) | 2015-05-20 | 2017-01-04 | 重庆药友制药有限责任公司 | 一种制备6α-烷基鹅去氧胆酸的方法 |
| PL3310801T3 (pl) | 2015-06-19 | 2021-11-22 | Intercept Pharmaceuticals, Inc. | Modulatory tgr5 i sposoby ich stosowania |
| CN106397522A (zh) | 2015-07-31 | 2017-02-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN106478756A (zh) | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技（武汉）有限公司 | Oca-e单晶及其制备方法和用途 |
| CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
-
2015
- 2015-11-19 CN CN201580062897.3A patent/CN107108688B/zh active Active
- 2015-11-19 EA EA201790879A patent/EA034739B1/ru unknown
- 2015-11-19 MX MX2017006565A patent/MX375865B/es active IP Right Grant
- 2015-11-19 EP EP15800911.8A patent/EP3221333B1/en active Active
- 2015-11-19 ES ES15800911T patent/ES2748692T3/es active Active
- 2015-11-19 PL PL15800911T patent/PL3221333T3/pl unknown
- 2015-11-19 WO PCT/GB2015/053518 patent/WO2016079519A1/en not_active Ceased
- 2015-11-19 JP JP2017527790A patent/JP6735748B2/ja active Active
- 2015-11-19 TW TW104138185A patent/TWI686401B/zh active
- 2015-11-19 US US15/528,331 patent/US10538550B2/en active Active
- 2015-11-19 KR KR1020177016857A patent/KR102546748B1/ko active Active
- 2015-11-19 DK DK15800911.8T patent/DK3221333T3/da active
- 2015-11-19 CA CA2968305A patent/CA2968305A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538690A5 (enExample) | ||
| JP2015533852A5 (enExample) | ||
| JP6696986B2 (ja) | ジアリールチオヒダントイン化合物の調製方法 | |
| JP2017534669A5 (enExample) | ||
| EP2802564B1 (en) | Process for the synthesis of etoricoxib | |
| JP2015512381A5 (enExample) | ||
| CN106117212B (zh) | 一种改进的西地那非合成工艺 | |
| JP2019523240A (ja) | テトラキス（トリヒドロカルビルホスファン）パラジウム（０）の製造方法 | |
| JP5039419B2 (ja) | クロスカップリング化合物の製造方法 | |
| JP2015063501A (ja) | ５−Ｘ（Ｘ＝Ｆ，Ｃｌ，Ｂｒ）−１，２−ベンズヨードキソール−３−（１Ｈ）−オン部位を有する新規超原子価ヨウ素化合物 | |
| CN112062739B (zh) | 一种将内酯还原为半缩醛的制备方法 | |
| JP5818278B2 (ja) | ペレチノインの向上した合成 | |
| JP5407332B2 (ja) | クォータピリジン誘導体の製造方法及びその中間体 | |
| JP5351103B2 (ja) | スルホニウム塩の製造方法およびそれによって製造されたスルホニウム塩 | |
| KR20080031910A (ko) | １-[시아노(４-하이드록시페닐)메틸]사이클로헥사놀화합물의 제조 방법 | |
| CN111454315A (zh) | 一种雄甾-16-烯-3β-醇的合成方法 | |
| JP5077796B2 (ja) | Ｏ、ｓ又はｎを含む鎖状アルキル化合物の製造方法 | |
| JP6085952B2 (ja) | ２−オキソプロパンスルトン化合物の製造方法 | |
| JP2014148494A (ja) | ５−ニトロ−１，２−ベンズヨードキソール−３−（１ｈ）−オン部位を有する新規超原子価ヨウ素化合物 | |
| TW201731806A (zh) | 製備羥基酪醇之方法 | |
| JPH07330654A (ja) | エーテル置換アルデヒド類の製造方法 | |
| JP2010083798A (ja) | ω−ヒドロキシ長鎖脂肪酸誘導体の製造方法 | |
| JP6433809B2 (ja) | １−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法 | |
| JPWO2013038931A1 (ja) | ２−オキソ−２Ｈ−シクロヘプタ［ｂ］フラン類縁体の製造方法 | |
| JP2011037724A (ja) | ピリミジニルアルコール誘導体の製造方法及びその合成中間体 |